Geneva-based Clee Medical has closed its Seed financing round to accelerate the development of its real-time intraoperative brain imaging platform, Neuro Access.
The round was led by High-Tech Gründerfonds, with participation from Zürcher Kantonalbank, Kickfund, FONGIT, and Venture Kick. Existing partner Wyss Geneva also continued its support. The newly secured capital will be used to advance product development, clinical validation, and regulatory preparation.
Bringing Real-Time Visibility Into The Operating Room
Neurosurgical procedures often rely heavily on pre-operative imaging, while the conditions inside the operating room can change dynamically. Anatomical shifts and limited intraoperative visibility can make precise targeting more challenging, particularly in minimally invasive stereotactic procedures that require millimeter-level accuracy.
Clee Medical’s Neuro Access platform is designed to address this gap. The technology provides ultra-high-resolution, real-time imaging inside the brain, enabling surgeons to visualize critical structures during procedures rather than relying solely on pre-surgical scans.
According to Co-Founder and CEO Matthew Lapinski, the goal is to introduce a new level of intraoperative visibility to support safer interventions and expand the capabilities of minimally invasive neurosurgery.
The platform builds on years of translational research and is being developed for applications including functional neurosurgery and neuro-oncology.
Advertisement
Accelerating Clinical Validation And Regulatory Milestones
With the Seed funding in place, Clee Medical plans to expand its development and clinical programs, including preparation for its first-in-human clinical study. Advancing toward early clinical adoption and regulatory milestones will be a central focus in the coming phase.
Tilmann Petersen, Investment Manager at High-Tech Gründerfonds, noted that real-time visualization during minimally invasive neurosurgical procedures represents a significant unmet need. He highlighted the experience of the founding team, which includes contributions to established neurosurgical platforms such as the StealthStation stereotactic system and the NeuroMate robotic platform.
Strengthening Switzerland’s Neurotechnology Ecosystem
The closing of the Seed round marks a transition from preclinical development to clinical translation for Clee Medical. Backed by a European investor syndicate and Swiss innovation partners, the company aims to move Neuro Access closer to practical use in operating rooms.
Clee Medical is led by co-founders Matthew Lapinski and Abed Hammoud. Lapinski brings experience in building and scaling Class III medical device startups in the United States, while Hammoud has worked on leading neurosurgical navigation and robotic systems.
The company’s long-term vision is to enhance surgical precision and improve outcomes in complex brain procedures by enabling real-time insight during surgery.
About Clee Medical
Clee Medical SA is a Swiss medical technology company based in Geneva developing minimally invasive neurotechnology solutions. Its Neuro Access platform integrates ultra-high-resolution real-time intraoperative imaging with advanced navigation capabilities to support precision neurosurgery. Founded in October 2024, the company focuses on improving surgical visibility and enabling safer access to deep brain targets.
